Among the three dosing arms in Argo Biopharma’s Phase II study of BW-20805, the 300 mg every-24-weeks group produced a 96% mean reduction in monthly hereditary angioedema attack rate over the first 169 days of treatment, with three out of four patients in that arm remaining completely attack-free. That figure, drawn from a June 2026 data cut across 24 evaluable participants, is the centerpiece of an oral presentation the company delivered at the Bradykinin Symposium 2026 in Berlin this week.
The other two regimens tracked closely. The 300 mg every-12-weeks arm cut monthly attack rates by 93%, with 62.5% of patients attack-free; the 600 mg every-24-weeks arm reduced rates by 83%, with half of patients attack-free over the same window. On the pharmacodynamic side, plasma prekallikrein suppression at Day 169 reached 85 to 94% across all three groups in the 19-patient PKK-evaluable subset. BW-20805 works by silencing hepatic prekallikrein mRNA, a validated target in HAE, and the dosing intervals tested, either every 12 or every 24 weeks, are notably longer than those of several existing prophylactic agents. The open-label, multicenter study enrolled adults with HAE type 1 or 2 at sites across multiple countries.
Safety across all 25 dosed participants was unremarkable in the ways that matter most for a prophylactic drug: no treatment discontinuations, no withdrawals, no deaths, and no participant met protocol hepatotoxicity thresholds. Injection-site reactions were the most frequently flagged adverse event of special interest, and most events were mild. That hepatic safety signal, or rather the absence of one, will draw attention given that RNA-silencing therapies targeting the liver have historically been watched closely on that dimension. The HAE prophylaxis market has expanded in recent years, with the FDA approving garadacimab (Andembry) for adults and adolescents aged 12 and older in 2025, so Argo will need Phase III data to differentiate on both efficacy durability and dosing convenience.
The number to track next is whether the 300 mg every-24-weeks arm holds its attack-free rate past Day 169. A single six-month dosing interval with three quarters of patients attack-free is a commercially relevant claim, but it rests on eight patients. A Phase III enrollment decision will clarify how much confidence the company places in that dose over the higher one.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
